| 55.12 -1.49 (-2.63%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 80.03 |
1-year : | 91.66 |
| Resists | First : | 68.52 |
Second : | 78.48 |
| Pivot price | 63.48 |
|||
| Supports | First : | 52.41 |
Second : | 43.61 |
| MAs | MA(5) : | 57.42 |
MA(20) : | 64.96 |
| MA(100) : | 59.17  |
MA(250) : | 48.64 |
|
| MACD | MACD : | -2.4 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 10.7 |
D(3) : | 8.5 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 78.48 | Low : | 30.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRSP ] has closed above bottom band by 11.9%. Bollinger Bands are 58% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 55.33 - 55.64 | 55.64 - 55.98 |
| Low: | 51.56 - 51.9 | 51.9 - 52.27 |
| Close: | 54.45 - 55.07 | 55.07 - 55.74 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Sun, 09 Nov 2025
CRSP Unveils Promising Phase 1 Results for Gene-Editing Therapy - GuruFocus
Sun, 09 Nov 2025
CRISPR Therapeutics Stock (CRSP) Opinions on CTX310 Phase 1 Data Release - Quiver Quantitative
Sat, 08 Nov 2025
CRISPR updates early-stage trial data for heart disease therapy - Seeking Alpha
Sat, 08 Nov 2025
CRISPR Therapeutics (Nasdaq: CRSP) announces 73% ANGPTL3 drop in Phase 1 CTX310 trial - Stock Titan
Sat, 08 Nov 2025
CRISPR Therapeutics AG $CRSP Shares Acquired by Vestmark Advisory Solutions Inc. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 9.045e+007 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 23,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.3725e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 918.2 % |
| Return on Equity (ttm) | -13.1 % |
| Qtrly Rev. Growth | 3.805e+007 % |
| Gross Profit (p.s.) | 39.4 |
| Sales Per Share | -13.78 |
| EBITDA (p.s.) | -2.07859e+008 |
| Qtrly Earnings Growth | -5.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -325 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -4.01 |
| Price to Cash Flow | 5.23 |
| Dividend | 0 |
| Forward Dividend | 2.105e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|